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BACKGROUND: Combining 2 signals of cardiomyocyte injury, cardiac troponin 
I (cTnI) and T (cTnT), might overcome some individual pathophysiological 
and analytical limitations and thereby increase diagnostic accuracy for acute 
myocardial infarction with a single blood draw. We aimed to evaluate the 
diagnostic performance of combinations of high-sensitivity (hs) cTnI and hs-cTnT 
for the early diagnosis of acute myocardial infarction.
METHODS: The diagnostic performance of combining hs-cTnI (Architect, 
Abbott) and hs-cTnT (Elecsys, Roche) concentrations (sum, product, ratio, and a 
combination algorithm) obtained at the time of presentation was evaluated in a 
large multicenter diagnostic study of patients with suspected acute myocardial 
infarction. The optimal rule-out and rule-in thresholds were externally 
validated in a second large multicenter diagnostic study. The proportion of 
patients eligible for early rule-out was compared with the European Society of 
Cardiology 0/1 and 0/3 hour algorithms.
RESULTS: Combining hs-cTnI and hs-cTnT concentrations did not consistently 
increase overall diagnostic accuracy as compared with the individual isoforms. 
However, the combination improved the proportion of patients meeting criteria 
for very early rule-out. With the European Society of Cardiology 2015 guideline 
recommended algorithms and cut-offs, the proportion meeting rule-out criteria 
after the baseline blood sampling was limited (6% to 24%) and assay dependent. 
Application of optimized cut-off values using the sum (9 ng/L) and product (18 
ng2/L2) of hs-cTnI and hs-cTnT concentrations led to an increase in the proportion 
ruled-out after a single blood draw to 34% to 41% in the original (sum: negative 
predictive value [NPV] 100% [95% confidence interval (CI), 99.5% to 100%]; 
product: NPV 100% [95% CI, 99.5% to 100%]) and in the validation cohort 
(sum: NPV 99.6% [95% CI, 99.0–99.9%]; product: NPV 99.4% [95% CI, 
98.8–99.8%]). The use of a combination algorithm (hs-cTnI <4 ng/L and hs-cTnT 
<9 ng/L) showed comparable results for rule-out (40% to 43% ruled out; NPV 
original cohort 99.9% [95% CI, 99.2–100%]; NPV validation cohort 99.5% [95% 
CI, 98.9–99.8%]) and rule-in (positive predictive value [PPV] original cohort 74.4% 
[95% Cl, 69.6–78.8%]; PPV validation cohort 84.0% [95% Cl, 79.7–87.6%]).
CONCLUSIONS: New strategies combining hs-cTnI and hs-cTnT concentrations 
may significantly increase the number of patients eligible for very early and safe 
rule-out, but do not seem helpful for the rule-in of acute myocardial infarction.
CLINICAL TRIAL REGISTRATION: URL (APACE): https://www.clinicaltrial.gov. 
Unique identifier: NCT00470587. URL (ADAPT): www.anzctr.org.au. Unique 
identifier: ACTRN12611001069943.
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Approximately 10% of all patients seeking medi-cal attention at the emergency department (ED) report chest discomfort, a complaint that 
reflects many potential causes, including acute myo-
cardial infarction (AMI).1 Rapid identification of pa-
tients with AMI is of profound clinical importance for 
fast initiation of medical treatment and management.2 
In addition, rapid rule-out of patients without AMI 
can overcome prolonged patient anxiety, unnecessary 
resource use, and overcrowding in the ED.3–7 Despite 
major improvements in diagnostic accuracy owing to 
the introduction of high-sensitivity cardiac troponin 
(hs-cTn) assays and data-driven optimized diagnostic 
algorithms, rapid, accurate, and safe rule-out based on 
a single measurement of hs-cTn is still possible only in 
a minority of patients.2,3,8,9
Current guidelines recommend measurement of 1 
of the cardiac specific isoforms of the cardiac tropo-
nin (cTn) complex: cTnI or cTnT.2,10 The development of 
high-sensitivity methods for the measurements of cTnT 
and cTnI concentrations has allowed the delineation of 
pathophysiological and analytical differences between 
cTnT and cTnI. First, hs-cTnT plasma concentrations 
exhibit a diurnal rhythm, whereas (hs)-cTnI does not.11 
Second, hs-cTnT concentrations seem to be a stronger 
predictor of death as compared with hs-cTnI concentra-
tions.12 Third, cTnI seems to be released from injured 
cardiomyocyte slightly earlier and possibly by less in-
tense injury as compared with cTnT.12 Fourth, the asso-
ciation with renal dysfunction is stronger for cTnT clear-
ance than for cTnI.13 Fifth, hemolysis, which is common 
in blood samples taken in the ED, seems to increase cTnI 
concentrations, but decrease cTnT concentrations.14 
Sixth, although analytically false-positive results overall 
seem rare with both hs-cTnT and hs-cTnI, they can be 
triggered by the re-expression of embryonic cTnT in the 
skeletal muscle of patients with neuromuscular disor-
ders for hs-cTnT and heterophilic antibodies to cTnI for 
hs-cTnI.15 Combining 2 signals of cardiomyocyte dam-
age, hs-cTnT and hs-cTnI, might overcome some indi-
vidual pathophysiological and analytical limitations and 
thereby increase diagnostic accuracy for AMI with a sin-
gle blood draw.11,16,17 Despite differences in biochemi-
cal characteristics and release kinetics,18,19 a recent di-
rect comparison between hs-cTnI and hs-cTnT showed 
similar, high diagnostic accuracy for AMI, emphasizing 
the similarities between both isoforms.12 Based on the 
observation of an imperfect correlation between blood 
concentrations of cTnT and cTnI in chronic and acute 
disorders,20,21 and in analogy to the quantification of re-
nal function using creatinine and cystatin C, where the 
combination of 2 parameters associated with the same 
pathophysiological process but influenced by distinct 
factors led to a more precise and accurate indicator,22 
we hypothesize that combining hs-cTnI and hs-cTnT 
concentrations will overcome independent pathophysi-
ological, preanalytical, and analytical differences of the 
individual molecules, and might therefore have higher 
diagnostic accuracy for AMI than either hs-cTnI or hs-
cTnT alone. This hypothesis was tested in 2 large pro-
spective, multicenter diagnostic studies.
METHODS
The data and study materials will not be made available to 
other researchers for purposes of reproducing the results 
or replicating the procedure. The analytical methods will be 
available on request.
Patients and Setting
The combination of hs-cTnI and hs-cTnT for the diagnosis of 
AMI was investigated in 2 diagnostic cohorts: The primary 
cohort was the APACE study (Advantageous Predictors of 
Acute Coronary Syndrome Evaluation),3,12,23,24 and the sec-
ondary (external validation) cohort was the New Zealand-
Australia combined data from the multicentre 2-Hour ADAPT 
study (Accelerated Diagnostic Protocol to Assess Patients With
Chest Pain Symptoms Using Contemporary Troponins as 
the Only Biomarker),25 the ADAPT-RCT, and the EDACS 
(Emergency Department Chest Pain Score)-RCT.26,27 For con-
venience we will refer to this combined cohort as the ADAPT 
cohort.
Clinical Perspective
What Is New?
• Measuring both cardiac troponin T (hs-cTnT) and 
cardiac troponin I (hs-cTnI) for the diagnosis of 
acute myocardial infarction does not consistently 
increase overall diagnostic accuracy as compared 
with measurement of the individual troponins.
• Using a combination of cTnT and cTnI concen-
trations, both obtained at a single blood draw at 
presentation, leads to a substantial increase in the 
proportion of patients in whom an acute myocar-
dial infarction can be safely excluded.
• In contrast, the combination of cTnT and cTnI does 
not improve the determination of patients with 
acute myocardial infarction.
What Are the Clinical Implications?
• Combining cTnT and cTnI may contribute to a clini-
cally relevant 3- to 6-fold increase in the number 
of rule-outs after a single blood draw at presenta-
tion compared with the current European Society 
of Cardiology 0/3 hour algorithms.
• The increased rule-out of myocardial infarction at 
presentation may reduce the number of patients 
who have to wait for a consecutive cardiac tro-
ponin measurement, and may therefore favorably 
impact resource use and overcrowding in the emer-
gency department.
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APACE is an ongoing prospective, international multi-
center diagnostic study that enrolls patients presenting to 
the ED with acute chest discomfort with an onset of peak 
within the last 12 hours. Patients are enrolled regardless of 
their renal function. Only patients with terminal kidney failure 
on chronic dialysis are excluded. This analysis contains data of 
patients enrolled between April 2006 and May 2013 who had 
a final diagnosis adjudicated by 2 independent cardiologists 
(n=3029). For this analysis, patients were excluded if hs-cTnI 
or hs-cTnT blood concentrations at presentation were not 
available (n=661), if the final adjudicated diagnosis was ST–
elevation myocardial infarction (n=74), or if the final diagnosis 
remained unclear after adjudication and ≥1 (hs)-cTn level was 
elevated (possibly indicating the presence of AMI; n=69).
In the ADAPT cohort, patients with ≥5 minutes of symp-
toms consistent with acute coronary syndrome,28 but without 
ST–segment elevation, were enrolled at 2 EDs in Brisbane, 
Australia and Christchurch, New Zealand between November 
2007 and July 2014.
Both studies were carried out according to the principles 
of the Declaration of Helsinki, approved by the local eth-
ics committees, and registered at clinicaltrial.gov (APACE: 
NCT00470587) or at the Australia-New Zealand Clinical 
Trials Registry (ADAPT: ACTRN12611001069943, ADAPT-
RCT: ACTRN12610000766011, EDACS-RCT: ACTRN1261 
3000745741). Written informed consent was obtained from 
all patients.
Routine Clinical Assessment
In both cohorts, patients underwent routine clinical assess-
ment that included medical history, physical examination, 
standard blood tests including serial measurements of local 
(hs)-cTn, 12-lead ECG, chest radiography, continuous ECG 
rhythm monitoring, and pulse oximetry. Management of 
patients was left to the discretion of the attending physician.
Adjudicated Final Diagnosis
In the APACE cohort, adjudication of the final diagnosis was 
performed by 2 independent cardiologists at the core labora-
tory (University Hospital Basel) applying the universal defini-
tion of AMI29 using 2 sets of data: first, all available medical 
records obtained during clinical care including history, physi-
cal examination, results of laboratory testing (including serial 
clinical (hs)-cTn concentrations, radiological testing, ECG, 
echocardiography, cardiac exercise test, lesion severity, and 
morphology in coronary angiography—pertaining to the 
patient from the time of ED presentation to 90-day follow-
up; second, study-specific assessments including detailed 
chest pain characteristics using 34 predefined criteria, serial 
hs-cTnT blood concentrations obtained from study samples, 
and clinical follow-up by telephone or by mail. In situations 
of disagreement about the diagnosis, cases were reviewed 
and adjudicated in conjunction with a third cardiologist. 
These procedures were comparable with those in the ADAPT 
cohort, where the adjudication of the final diagnosis was 
performed by 2 independent cardiologists blind to results 
of the index-test biomarkers under investigation, but with 
knowledge of the clinical record, ECG, and serial cTnI results 
from routine care (details of adjudication are given in the 
online-only Data Supplement).
In both cohorts, AMI was defined and (hs-)cTn interpreted 
as recommended in the current guidelines.2,30,31 In brief, AMI 
was diagnosed when there was evidence of myocardial necro-
sis in association with a clinical setting consistent with myocar-
dial ischemia. Myocardial necrosis was diagnosed by ≥1 cTn 
value >99th percentile (or for the conventional cTn assays >10% 
imprecision value if not fulfilled at the 99th percentile) together 
with a significant rise or fall. The criteria used to define a rise 
or fall in conventional cTn and hs-cTnT are described in detail 
in the Method section in the online-only Data Supplement. 
All other patients were classified in the categories of unstable 
angina, noncardiac chest pain, cardiac but noncoronary dis-
ease (eg, tachyarrhythmias, perimyocarditis), and symptoms of 
unknown origin with normal concentrations of hs-cTnT.
Measurement of hs-cTnT and hs-cTnI
After centrifugation, serum was frozen at −80°C until mea-
surement with hs-cTn assays. Hs-cTnI was measured by using 
the ARCHITECT High Sensitive STAT Troponin I assay (Abbott 
Laboratories). According to the manufacturer, the 99th per-
centile concentration is 26.2 ng/L, with a corresponding coef-
ficient of variation of <5%.32 Hs-cTnT was measured with 
the Roche hs-cTnT assay. The 99th percentile among healthy 
subjects is 14 ng/L, with a 10% analytical variation at 13 
ng/L.33 Data presented here were not affected by the 2010 
to 2012 hs-cTnT low-end shift in APACE and appropriately 
corrected in ADAPT.34–36 Calculation of the glomerular filtra-
tion rate was performed using the abbreviated Modification 
of Diet in Renal Disease formula.37
Statistical Analysis
We evaluated the diagnostic accuracy and performance of 
the combined hs-cTnI and hs-cTnT measurement in 2 dif-
ferent ways: First, we examined sum, product, and ratio. 
Second, we derived and tested a combination algorithm of 
hs-cTnI and hs-cTnT. Data are expressed as median ± inter-
quartile range (IQR) for continuous variables and as numbers 
(n) and percentages (%) for categorical variables. Continuous 
variables were compared with the Mann–Whitney U test, and 
categorical variables were compared by use of the Pearson 
χ2 test. Cohen’s κ statistic was used to examine the agree-
ment between rule-in and rule-out at presentation based on 
hs-cTnT and hs-cTnI according to the 2 diagnostic algorithms 
recommended with a class I recommendation in the current 
European Society of Cardiology (ESC) guidelines: the 0/3h-hs-
cTn-algorithm and the 0h/1h-hs-cTn-algorithm.2 Sum, prod-
uct, and ratio were calculated from raw data. Undetectable 
low concentrations were assigned the concentration 0.1ng/L. 
Binary logistic regression analyses were used to calculate pre-
dicted probabilities for combined test variables.
Receiver-operating characteristics curves were constructed 
to assess diagnostic performance at presentation and 1h 
after initial presentation including the absolute change value. 
Diagnostic accuracy was reported as the area under the 
Receiver-operating characteristics curve (AUC) and the corre-
sponding 95% confidence intervals (95% CI). The compari-
son of dependent and independent AUCs was performed as 
recommended by Hanley and McNeil38 and for nested models 
with the comparison of −2 likelihood ratios as appropriate. Zero 
hour and 0h/1h serial sampled hs-cTn blood concentrations 
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were combined to represent the current gold standard of clini-
cal care as suggested in the 2015 ESC guidelines.2 Furthermore, 
integrated discrimination improvement was calculated.39
For the determination of optimal cut-off values for sum, 
product, and ratio (minimal negative predictive value [NPV] 
of 99.6% and a PPV of 75.0%, respectively, to match the 
performance of the 0h/1h-hs-cTn-algorithm2,40,41), the cohort 
was randomly divided in a derivation (80% of patients) and a 
validation subcohort (20% of patients).
For the cut-off values in the combination algorithm, the 
optimal rule-out combination was that which maximized the 
percentage ruled-out at a sensitivity of 99% and the optimal 
rule-in combination was that which maximized the percent-
age ruled-in at a PPV of 75%. We determined the optimal 
combination of hs-cTn thresholds based on a smoothed aver-
age of 500 bootstraps of the original cohort, in which we 
varied the hs-cTn threshold for each troponin assay in steps of 
0.1 ng/L. This methodology is more extensively described in 
the Methods section in the online-only Data Supplement. We 
used an ‘AND’ approach to ensure a safe early rule-out, and 
an ‘OR’ approach to maximize rule-in.
All hypothesis testing was 2-tailed, and values of P<0.05 
were considered statistically significant. We did not adjust 
for multiple testing. Statistical analyses were performed with 
SPSS for Windows 23.0 (SPSS Inc), MedCalc 9.6.4.0 (MedCalc 
software), and R version 3.2.4 (with packages ‘boot’ v1.3–18 
and ‘fields’ v8.10).
RESULTS
Distribution of hs-cTn Concentrations at 
Presentation in Patients With Suspected 
AMI
Baseline characteristics of 2225 patients in the APACE 
cohort presenting to the ED with suspected AMI are 
shown in Table I in the online-only Data Supplement. The 
adjudicated final diagnosis was AMI (non–ST–elevation 
myocardial infarction) in 18% of patients (85% had type 
I and 15% type II AMI), unstable angina in 10%, car-
diac but not coronary artery disease in 14%, noncardiac 
chest pain in 54%, and symptoms of unknown origin in 
5%. AMI patients had higher concentrations of hs-cTnI 
and hs-cTnT at presentation compared with the no-AMI 
group (hs-cTnI median 115.2 ng/L (IQR: 21.7–632.9) 
versus 3.5 ng/L (IQR: 2.2–7.2) P<0.001; hs-cTnT median 
64.1 ng/L (IQR: 28.0–152.4) versus 7.0 ng/L (IQR: 4.0–
12.4) P<0.001; Table II in the online-only Data Supple-
ment and Figure I in the online-only Data Supplement). 
The correlation between hs-cTnI and hs-cTnT concentra-
tions at presentation was high (r=0.89; Figure 1).
Diagnostic Performance of hs-cTn 
Concentrations Measured at Presentation 
According to the ESC 0/3-Hour Algorithm
In the APACE cohort 721 of 2225 patients (32.4%) 
presented ≥6h after onset of chest pain and therefore 
could be assessed by the late-presenter part of the ESC 
0/3h algorithm with a single blood draw. Using hs-cTnT, 
AMI could be ruled-out in 441 patients (19.8% of over-
all cohort, 61.2% of late-presenters) by a baseline hs-
cTn below the 99th percentile, and 4 AMIs were missed. 
Adding the clinical information (GRACE score <140 and 
pain free) resulted in 1 missed AMI and therefore in a 
sensitivity of 99.3% (95% Cl, 96.2–100%) and a NPV 
of 99.4% (95% Cl, 96.8–100%).
Using hs-cTnI, in 539 patients (24.2% of overall co-
hort, 74.8% of late-presenters) AMI could be ruled-out 
by a single blood draw at presentation, and 21 AMIs 
were missed. Adding the clinical information reduced the 
number to 3 missed AMIs; sensitivity 97.9% (95% Cl, 
94.0–99.6%) and NPV 98.5% (95% Cl, 95.7–99.7%). 
The agreement on patient allocation between hs-cTnI 
and hs-cTnT for rule-out at presentation was good 
(κ=0.90; Table IV in the online-only Data Supplement).
Diagnostic Performance of hs-cTn 
Concentrations Measured at Presentation 
According to the ESC 0/1-Hour Algorithm
AMI could be ruled-out in 149 (6.7%, sensitivity 100%, 
NPV 100%) and 235 (10.6%, sensitivity 100%, NPV 
100%) patients after a single blood draw at presenta-
tion, using hs-cTnI and hs-cTnT, respectively. Direct rule-
in could be achieved in 331 (14.9%, specificity 95.6%, 
PPV 75.5%) and 273 (12.3%, specificity 2.4%, PPV 
84.2%) subjects, using hs-cTnI or hs-cTnT, respectively. 
The agreement on patient allocation at presentation 
between hs-cTnI and hs-cTnT was moderate for rule-
out (κ=0.42) and good for rule-in (κ=0.79; Tables V and 
VI in the online-only Data Supplement). Using the 0/1-
hour algorithm 77% to 78% of patients need a second 
cardiac troponin measurement.
Figure 1. Log (base 10)-scale scatter plot of high-sensitivity cardiac 
troponin T (hs-cTnT) and high-sensitivity cardiac troponin I (hs-cTnI) 
at presentation in the Advantageous Predictors of Acute Coronary 
Syndrome Evaluation (APACE) cohort. 
Log-scale scatter plot displaying hs-cTnI and hs-cTnT concentrations at 
presentation in the APACE cohort (n=2225). The correlation coefficient is high 
(Pearson’s r=0.89).
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Diagnostic Performance of Combined 
hs-cTnI and hs-cTnT Concentrations 
Measured at Presentation
The diagnostic accuracy in the APACE cohort, as quanti-
fied by AUC, was evidently lower for the ratio than for 
the sum, product, or combination of hs-cTn and for the 
individual isoforms alone (Table 1 and Figure 2). Addition 
of a second isoform to 0h hs-cTn led to a numerically 
small increase in AUC above that for hs-cTnT alone, but 
not for hs-cTnI alone. Furthermore, addition of a com-
bined measurement at presentation to the 0h and 0h/1h 
change concentrations led to a numerically small, but 
statistically significant improvement in diagnostic accu-
racy of hs-cTnI, but not of hs-cTnT (Table VII in the on-
line-only Data Supplement). Reclassification statistics (in-
tegrated discrimination improvement) did not uniformly 
show incremental value of combining cardiac troponins 
at presentation when applied to the APACE cohort (Ta-
ble VIII in the online-only Data Supplement). Diagnostic 
performance did not increase when 2 different cardiac 
troponin I signals were combined (Siemens c-TnI Ultra, 
Beckman hs-cTnI, and Siemens hs-cTnI Vista; Tables IX 
through XI in the online-only Data Supplement). Compa-
rable results were found when hs-cTnI and hs-cTnT were 
combined using logistic regression analysis (Methods and 
Results sections in the online-only Data Supplement).
Early Allocation Based on Sum and 
Product
We examined the use of sum and product on the alloca-
tion of patients at presentation. In a randomly selected 
derivation cohort of 1799 patients (313 AMI, 1486 no 
AMI), thresholds for rule-out and rule-in achieving a NPV 
of ≥99.6% and a PPV of 75.0%, respectively, were rule-
out cut-off for the sum of 9 ng/L and for the product 
of 18 ng2/L2 (NPV both 100% [95% CI, 99.4–100%]), 
and a rule-in cut-off for the sum of 99 ng/L and for the 
product of 1608 ng2/L2 (PPV sum 75.1% [95% CI, 69.3–
80.3%], PPV product 75.1% [95% CI, 69.5–80.1%]). 
When these cut-off values were applied to the internal 
validation cohort of 426 patients (85 AMI, 341 no AMI), 
we found comparable results for sum (rule-out: sensi-
tivity 100% [95.8–100%], NPV 100% [97.5–100%]; 
rule-in: specificity 96.8% [94.3–98.4%], PPV 83.6% 
[72.4–91.6%]) and product (rule-out: sensitivity 100% 
[95.8–100%], NPV 100% [97.5–100%]; rule-in: speci-
ficity 96.8% [94.3–98.4%], PPV 83.6% [72.4–91.6%]; 
Tables 2 and 3). Application of these cut-off values in 
the original cohort (APACE) would cause a 3- to 5-fold 
increase in the number of rule-outs at presentation as 
compared with the 2015 ESC algorithms. This would 
decrease the percentage of patients that require a sec-
ond cardiac troponin measurement one hour later from 
77% to 78% to 50% to 52%.
When these cut-off values were applied to the ex-
ternal validation cohort (for patient characteristics see 
Table III in the online-only Data Supplement) of 2537 
patients (408 AMI, 2129 no AMI), we found compa-
rable results for sum (rule-out: sensitivity 99.0% [97.5–
99.7%]; NPV 99.6%; [99.0–99.9%] rule-in: specificity 
98.2% [97.5–98.7%]; PPV 87.5% [83.3–91.0%]) and 
product (rule-out: sensitivity 98.5% [96.8–99.5%], 
NPV 99.4% [98.8–99.8%]; rule-in: specificity 98.0% 
[97.3–98.5%], PPV 83.6% [83.2–90.6%]; Tables 2 and 
3). Applying sum and product for rule-in and rule-out 
would lead to 45% to 49% of subjects that require a 
second cardiac troponin measurement after an hour in 
the ADAPT cohort.
Details of the subjects that were falsely ruled-out us-
ing sum and product are reported in Tables XII and XIII 
in the online-only Data Supplement.
Early Allocation Based on a Combination 
Algorithm Consisting of hs-cTnI and hs-
cTnT
The optimal cut-off combination with an NPV of at least 
99.6% was hs-cTnT < 9.8 ng/L and hs-cTnI < 4.8 ng/L. 
From a pragmatic point of view, we rounded these 
cut-off concentrations down to hs-cTnT <9 ng/L and 
hs-cTnI <4 ng/L. In the original cohort (APACE) these 
thresholds combine to rule-out 48.4% of patients, to a 
4-to-6-fold increase in the number of rule-outs at pre-
Table 1. Diagnostic Accuracy of hs-cTnI, hs-cTnT, the Combination, Sum, Product, and Ratio for the Diagnosis of 
Acute Myocardial Infarction at Presentation
Parameter
Area Under the Curve  
(95% Confidence Interval)
Compared With hs-
cTnI Alone (P Value)
Compared With hs-cTnT 
Alone (P Value)
hs-cTnI alone 0.93 (0.92–0.94)  0.714
hs-cTnT alone 0.93 (0.92–0.94) 0.714  
hs-cTnI <4ng/L and hs-cTnT <9ng/L 0.93 (0.92–0.94) 0.789 0.002
Sum (hs-cTnI + hs-cTnT) 0.94 (0.93–0.95) 0.053 0.114
Product (hs-cTnI × hs-cTnT) 0.94 (0.93–0.95) 0.007 0.078
Ratio (hs-cTnI/hs-cTnT) 0.79 (0.78–0.81) <0.001 <0.001
hs-cTnI indicates high-sensitivity cardiac troponin I; and hs-cTnT, high-sensitivity cardiac troponin T.
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sentation than the ESC 0/3h algorithm. In the exter-
nal validation cohort the optimal rule-out combination 
would rule-out >50% of subjects (sensitivity 98.8% 
[97.2–99.6%], NPV 99.5% [98.9–99.9%]). The NPV in 
the external validation cohort was lower than the one 
in the original cohort (Table 4). Details of the subjects 
that were falsely ruled-out using this combination algo-
rithm are reported in Tables XII and XIII in the online-
only Data Supplement.
The optimal cut-off combination for rule-in was 
hs-cTnT ≥ 57 ng/L OR hs-cTnI ≥ 54 ng/L which in the 
APACE cohort ruled-in 259 (65.1%) of AMI patients. 
In the external validation cohort, 293 (71.8%) patients 
with a final diagnosis of AMI subjects would be ruled 
in (specificity 97.4% [93.7–95.6%], PPV 84.0% [79.7–
87.6%]; Table 5). This would lead to 43% of patients 
that require a second cardiac troponin measurement 
after an hour.
DISCUSSION
We evaluated 4 methods to combine cTnI and cTnT for 
the early diagnosis of AMI in 2 large prospective diag-
nostic multicenter studies, and report 3 major findings.
First, the number of direct rule-outs at presentation 
using the algorithms of the current ESC guidelines2 is 
limited (7% to 13% of subjects without an AMI) and 
assay-dependent. Second, the difference in diagnostic 
accuracy between the combinations of the cTn mea-
sured by the 2 assays and a cTn measurement by either 
assay alone is numerically small (except for when com-
bined as a ratio). In addition, the results of the reclassi-
fication statistics indicated that the application of 2 cTn 
isoforms at presentation may add incremental value, 
but that this is not the case for the sum and product 
when applied to the whole cohort. Third, combining 
cardiac hs-cTnI and hs-cTnT, using the sum and product 
or a combination algorithm, achieved a very high NPV 
and led to a 3- to 6-fold increase in the number of rule-
outs after a single blood draw compared with the ESC 
algorithms.
The findings from this study corroborate and extend 
previous work aiming to further improve the safety and 
efficacy of the rule-out and rule-in of AMI among pa-
tients presenting with acute chest discomfort to the 
ED.2–4,6,7,8,42–44 The findings from this study corroborate 
and extend previous work aiming to further improve 
the safety and efficacy of the rule-out and rule-in of 
AMI among patients presenting with acute chest dis-
comfort to the ED (quote), including 2 large meta-anal-
yses providing exact estimates for the performance of 
single measurement rule-out strategies using very low 
Figure 2. Receiver-operating characteristic curves of the diagnostic 
performance of high-sensitivity cardiac troponins (hs-cTns) and their 
ratio, sum, and product for non–ST–elevation myocardial infarction 
(NSTEMI) in the Advantageous Predictors of Acute Coronary Syndrome 
Evaluation (APACE) cohort. 
Diagnostic performance of hs-cTn for non-ST segment myocardial infarction 
at presentation to the emergency department with acute chest pain. ROC 
curves show the diagnostic accuracy of hs-cTnI and hs-cTnT, their ratio, sum, 
and product.
Table 2. Performance of Sum and Product for Rule-Out
 
Original Cohort 
(n=2225; 398 AMI, 
1827 no AMI)
External Validation 
Cohort (n=2537; 408 
AMI, 2129 no AMI)
Sum <9 ng/L
  All subjects 746 (33.5) 988 (38.9)
  AMI 0 (0.0) 4 (1.0)
  No AMI 746 (40.8) 984 (46.2)
  Negative predictive value 100 (99.5–100) 99.6 (99.0–99.9)
Product <18 ng2/L2
  All subjects 782 (35.1) 1047 (41.3)
  AMI 0 (0.0) 6 (1.5)
  No AMI 782 (42.8) 1041 (48.9)
  Negative predictive value 100 (99.5–100) 99.4 (98.8–99.8)
Values are n (%) or % (range). 
AMI indicates acute myocardial infarction.
Table 3. Performance of Sum and Product for Rule-In
 
Original Cohort 
(n=2225; 398 AMI, 
1827 no AMI)
External Validation 
Cohort (n=2537; 408 
AMI, 2129 no AMI)
Sum >99 ng/L
  All subjects 324 (14.6) 312 (12.3)
  AMI 249 (62.2) 273 (66.9)
  No AMI 75 (4.1) 39 (1.8)
  Positive predictive value 76.9 (71.8–81.3) 87.5 (83.3–91.0)
Product >1608 ng2/L2
  All subjects 340 (15.3) 337 (13.3)
  AMI 261 (65.6) 294 (72.1)
  No AMI 79 (4.3) 43 (2.0)
  Positive predictive value 76.8 (71.9–81.2) 87.2 (83.2–90.6)
Values are n (%) or % (range). AMI indicates acute myocardial infarction.
D
ow
nloaded from
 http://ahajournals.org by on March 13, 2019
van der Linden et al Combining Troponin T and I for Diagnosis of AMI
Circulation. 2018;138:989–999. DOI: 10.1161/CIRCULATIONAHA.117.032003 September 4, 2018 995
ORIGINAL RESEARCH 
ARTICLE
concentrations of hs-cTnT and hs-cTnI (quote).45,46 To 
the best of our knowledge this work is the first system-
atic approach testing the clinical utility of combinations 
of hs-cTnI and hs-cTnT, the 2 most accurate biochemical 
signals in the early diagnosis of AMI.2–4,6,43,44 Although 
there is broad agreement that hs-cTnI or hs-cTnT should 
be used as a key component in any AMI rule-out algo-
rithm,2,7,10,47,48 it has remained unclear whether a sec-
ond biochemical signature could provide enough incre-
mental value to potentially justify routine clinical use.
Although when used in conjunction with less sen-
sitive cTn assays, some additional biochemical signals 
including copeptin and heart-type fatty acid–binding 
protein were able to provide incremental diagnostic 
value, this was no longer the case when using hs-cTnT 
or hs-cTnI as recommended in current guidelines.49–54 
The only additional analyte that recently was suggested 
to possibly provide incremental diagnostic value even 
if using hs-cTnT is cardiac myosin-binding protein C, a 
quantitative marker of cardiomyocyte injury that seems 
even more rapidly released from injured cardiomyocytes 
as compared with hs-cTnT and hs-cTnI.55
The novel concept investigated in this study was 
based on recent studies documenting that there could 
be remarkable differences between the cTnI and the 
cTnT signal, and the moderate agreement between 
clinical decisions made on these concentrations.20,56,57 
We hypothesized that combining the 2 biochemical sig-
nals might overcome independent pathophysiological, 
preanalytical, and analytical differences between the 
individual molecules such as (auto)antibodies and sug-
gested interference with troponin released from skeletal 
muscle,12,15,58,59 and might therefore have higher diag-
nostic accuracy for AMI than either cTnI or cTnT alone.
This study shows that combining hs-cTnI and hs-cTnT 
may contribute to a clinically relevant increase in the 
number of rule-outs at presentation. The small increase 
in false-negative results when the derived thresholds 
were applied in the external validation cohort raises the 
question what is considered a still acceptable number 
of false rule-ins and rule-outs.60 Furthermore, it illus-
trates the outlier-dependency of the determination of 
very low cut-off values, and advocates the use of ex-
tended (pooled) cohorts and the recalibration of cut-off 
values for the determination of more universally appli-
cable decision rules.61 A second point that merits atten-
tion are the, at first sight contrary, unconvincing results 
of the diagnostic accuracy and reclassification statistics. 
Because the AUC is already very high for either hs-cTn 
alone and because it is based on ranking with the large 
numbers of patients below the limit of detection having 
the same rank, the signal from an additional biomarker 
to increase the AUC would need to be massive and 
the biomarker itself may need to be a better marker 
even than hs-cTn. These findings are of limited addi-
tional value for the whole population, whereas comb-
ing hs-cTnI and hs-cTnT might be especially valuable in 
patients with low hs-cTn concentrations at presenta-
tion. Another reason for this discrepancy might be the 
3-group (rule-out, observational, rule-in) approach that 
is used for the diagnosis of AMI and its outlier depen-
dency.
Table 4. Performance of the Combination Approach for Rule-Out
 
Original Cohort 
(n=2225; 398 AMI, 
1827 no AMI)
External Validation 
Cohort (n=2537; 408 
AMI, 2129 no AMI)
hs-cTnI <4 ng/L and hs-cTnT <9 ng/L
  All subjects 886 (39.8) 1088 (42.9)
  AMI 1 (0.3) 5 (1.2)
  No AMI 885 (48.4) 1083 (50.9)
  Negative predictive value 99.9 (99.2–100) 99.5 (98.9–99.8)
hs-cTnI <4 ng/L
  All subjects 1021 (45.9) 1210 (47.7)
  AMI 5 (1.3) 6 (1.5)
  No AMI 1016 (55.6) 1204 (56.6)
  Negative predictive value 99.5 (98.9–99.8) 99.5 (98.9–99.8)
hs-cTnT <9 ng/L
  All subjects 1117 (50.2) 1440 (56.8)
  AMI 12 (3.0) 16 (3.9)
  No AMI 1105 (60.5) 1424 (66.9)
  Negative predictive value 98.9 (98.1–99.4) 98.9 (93.7–97.7)
Values are n (%) or % (range). 
AMI indicates acute myocardial infarction; hs-cTnI, high-sensitivity cardiac 
troponin I; and hs-cTnT, high-sensitivity cardiac troponin T.
Table 5. Performance of the Combination Approach for Rule-In
 
Original Cohort 
(n=2225; 398 AMI, 
1827 no AMI)
External Validation 
Cohort (n=2537; 408 
AMI, 2129 no AMI)
hs-cTnI ≥54 ng/L or hs-cTnT ≥57 ng/L
  All subjects 348 (15.6) 349 (13.8)
  AMI 259 (65.1) 293 (71.8)
  No AMI 89 (4.9) 56 (2.6)
  Positive predictive value 74.4 (69.6–78.8) 84.0 (79.7–87.6)
hs-cTnI ≥54 ng/L
  All subjects 327 (14.7) 322 (12.7)
  AMI 247 (62.1) 283 (69.4)
  No AMI 80 (4.4) 39 (1.8)
  Positive predictive value 75.5 (70.4–80.0) 87.9 (83.8–91.2)
hs-cTnT ≥57 ng/L
  All subjects 256 (11.5) 240 (9.5)
  AMI 218 (54.8) 206 (50.5)
  No AMI 38 (2.1) 34 (1.6)
  Positive predictive value 85.2 (80.1–89.2) 85.8 (80.8–90.0)
Values are n (%) or % (range). AMI indicates acute myocardial infarction; 
hs-cTnI, high-sensitivity cardiac troponin I; and hs-cTnT, high-sensitivity cardiac 
troponin T.
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The clinical implementation of a dual-marker ap-
proach combining cTnI and cTnT would likely be as-
sociated with substantial logistic obstacles because no 
diagnostic company currently is able to provide both 
hs-cTnT and hs-cTnI assays on the same laboratory plat-
form. In addition, most hospitals currently do not have 
analyzers for both analytes running on a 24/7 basis or 
even have only the platform for 1 of the assays at all. 
Therefore, the cost-effective clinical implementation of 
the dual-marker approach would require either addi-
tional investment in infrastructure by the laboratories 
(installing another platform) or collaboration among 
diagnostic companies for the provision of both hs-cTnT 
and hs-cTnI assays on the analyzer that is used for clini-
cal chemistry routine. The clinical implementation of a 
dual-marker approach combining cTnI and cTnT would 
likely be associated also with substantial educational ef-
forts for clinicians working in the ED, as 2 similar, yet 
different analytes with different clinical decision values 
would then be in clinical use at the same institution. 
Nevertheless, rapid and safe clinical decision making 
based on a single hs-cTn measurement at presentation 
seems to be approaching its limits, and the exploration 
of new diagnostic strategies including combinations of 
biomarkers, risk-assessment scores, or imaging seems 
to be indicated.8 From this point of view, overcoming 
these logistic obstacles by close collaboration between 
diagnostic companies, hospital laboratories, medi-
cal doctors, and researchers would be able to provide 
substantial medical value for patients and physicians, 
and economic value for hospitals and the health care 
system in general. Future studies are necessary to iden-
tify the best strategy and to better quantify the pos-
sible clinical benefit associated with the combination of 
cTnI and cTnT. Considering the relevant unmet clinical 
need as quantified by the high percentage of rule-out 
mismatches, the substantial increase in early rule-outs 
compared with the current ESC 0h/1h-algorithm and 
the substantial cost savings associated with reductions 
in the length of stay in the ED,62 dedicated economic 
analyses can be expected to show substantial reduc-
tions in time to decision, time to discharge, and there-
fore treatment costs. Consecutive studies to objectify 
these claims are indicated. Furthermore, it is important 
to highlight that despite the very high diagnostic ac-
curacy, hs-cTns and their combinations will always have 
to be used clinically only in conjunction with full clinical 
assessment including detailed patient history, physical 
examination, and the ECG.2
Some limitations of this study merit consideration. 
First, the central adjudication by 2 independent cardi-
ologists based on the clinical dataset, including cardiac 
imaging and serial measurements of the local (hs)-cTn 
and the study-specific dataset including 34 chest pain 
characteristics, serial measurements of hs-cTnT, and 
follow-up in the APACE study, represents the highest 
quality possible in a diagnostic study. However, it pos-
sibly introduced a very small but unavoidable disadvan-
tage for hs-cTnI regarding diagnostic accuracy. This is 
at large counterbalanced by the use of (h)s-cTnI for the 
adjudication ADAPT, as this possibly introduced a very 
small but unavoidable disadvantage for hs-cTnT regard-
ing diagnostic accuracy. Second, patients with terminal 
kidney failure on chronic dialysis were excluded from 
APACE. Accordingly, we cannot comment on the pos-
sible clinical utility of the combination approach in 
these vulnerable patients. Third, the method we used 
to determine the cut-off values for the combination 
algorithm could not produce very smooth curves for 
rule-in. Alternative methods may therefore provide bet-
ter results for rule-in. Fourth, an alternative approach 
to combine both cardiac troponins would be logistic 
regression. As shown in the online-only Data Supple-
ment, this led to comparable results. Nevertheless, the 
strong correlation between cardiac troponins may lead 
to spurious beta coefficients, and therefore we did not 
use this method for our primary results.63
In conclusion, diagnostic strategies combining cTnI 
and cTnT measurements, sum, product, or a combina-
tion algorithm may significantly increase the number 
of patients eligible for very early and safe rule-out, but 
does not seem helpful for the rule-in of AMI.
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